Market Cap | 2.65B | P/E | - | EPS this Y | -62.20% | Ern Qtrly Grth | - |
Income | -173.58M | Forward P/E | -17.85 | EPS next Y | -21.90% | 50D Avg Chg | 8.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 38.00% |
Dividend | N/A | Price/Book | 5.96 | EPS next 5Y | - | 52W High Chg | -8.00% |
Recommedations | 1.50 | Quick Ratio | 17.23 | Shares Outstanding | 65.11M | 52W Low Chg | 225.00% |
Insider Own | 2.89% | ROA | -22.71% | Shares Float | 35.55M | Beta | 1.28 |
Inst Own | 103.32% | ROE | -32.81% | Shares Shorted/Prior | 6.41M/6.83M | Price | 46.59 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 294,537 | Target Price | 112.40 |
Oper. Margin | - | Earnings Date | - | Volume | 216,336 | Change | -5.00% |
Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Guggenheim | Buy | Sep 16, 24 |
Wedbush | Outperform | Sep 16, 24 |
BMO Capital | Outperform | Sep 16, 24 |
Stifel | Buy | Sep 16, 24 |
Wedbush | Outperform | Sep 9, 24 |
JP Morgan | Overweight | Sep 4, 24 |
Barclays | Overweight | Aug 29, 24 |
Stifel | Buy | Jul 10, 24 |
Wedbush | Outperform | May 17, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Shair Matthew | Director Director | Dec 26 | Sell | 75.17 | 119,150 | 8,956,506 | 1,724,698 | 12/28/23 |
Protopapas Anna | Director Director | Dec 18 | Sell | 75.67 | 5,000 | 378,350 | 12/20/23 | |
Protopapas Anna | Director Director | Dec 18 | Option | 9.36 | 5,000 | 46,800 | 5,000 | 12/20/23 |
Noci Darlene | Chief Development Of.. Chief Development Officer | Dec 18 | Sell | 75.82 | 40,000 | 3,032,800 | 12/20/23 | |
Noci Darlene | Chief Development Of.. Chief Development Officer | Dec 18 | Option | 7.46 | 40,000 | 298,400 | 40,000 | 12/20/23 |
Miller Deborah Ann | Chief Legal Officer Chief Legal Officer | Dec 18 | Sell | 75.41 | 38,046 | 2,869,049 | 12/20/23 | |
Miller Deborah Ann | Chief Legal Officer Chief Legal Officer | Dec 18 | Option | 23.39 | 38,046 | 889,896 | 5,000 | 12/20/23 |
Balcom Alexandra | Chief Financial Offi.. Chief Financial Officer | Dec 18 | Option | 1.08 | 30,000 | 32,400 | 30,000 | 12/20/23 |
Balcom Alexandra | Chief Financial Offi.. Chief Financial Officer | Dec 18 | Sell | 75.82 | 30,000 | 2,274,600 | 12/20/23 | |
Shair Matthew | Director Director | Nov 28 | Sell | 62.03 | 9,150 | 567,574 | 1,843,848 | 11/30/23 |
Shair Matthew | Director Director | Oct 24 | Sell | 50.93 | 91,700 | 4,670,281 | 1,852,998 | 10/26/23 |
Turner Christopher Durant | Chief Medical Office.. Chief Medical Officer | Oct 04 | Sell | 55.01 | 7,995 | 439,805 | 14,513 | 10/06/23 |
Turner Christopher Durant | Chief Medical Office.. Chief Medical Officer | Oct 04 | Option | 6.89 | 7,995 | 55,086 | 22,508 | 10/06/23 |
Noci Darlene | Chief Development Of.. Chief Development Officer | Oct 04 | Sell | 56.48 | 20,000 | 1,129,600 | 10/06/23 | |
Noci Darlene | Chief Development Of.. Chief Development Officer | Oct 04 | Option | 3.99 | 20,000 | 79,800 | 20,000 | 10/06/23 |
Noci Darlene | Chief Development Of.. Chief Development Officer | Aug 01 | Sell | 49.88 | 3,000 | 149,640 | 08/01/23 | |
Noci Darlene | Chief Development Of.. Chief Development Officer | Aug 01 | Option | 1.08 | 3,000 | 3,240 | 3,000 | 08/01/23 |
Turner Christopher Durant | Chief Medical Office.. Chief Medical Officer | Jul 26 | Option | 6.89 | 5,030 | 34,657 | 17,178 | 07/28/23 |
Turner Christopher Durant | Chief Medical Office.. Chief Medical Officer | Jul 26 | Sell | 47.89 | 5,030 | 240,887 | 14,513 | 07/28/23 |
Turner Christopher Durant | Chief Medical Office.. Chief Medical Officer | Jul 20 | Sell | 46.81 | 300 | 14,043 | 14,513 | 07/24/23 |
Turner Christopher Durant | Chief Medical Office.. Chief Medical Officer | Jul 20 | Option | 6.89 | 300 | 2,067 | 14,713 | 07/24/23 |
Noci Darlene | Chief Development Of.. Chief Development Officer | Jul 03 | Sell | 41.73 | 3,000 | 125,190 | 07/06/23 | |
Noci Darlene | Chief Development Of.. Chief Development Officer | Jul 03 | Option | 1.08 | 3,000 | 3,240 | 3,000 | 07/06/23 |
Miller Deborah Ann | Chief Legal Officer Chief Legal Officer | May 05 | Sell | 39.64 | 4,132 | 163,792 | 05/09/23 | |
Miller Deborah Ann | Chief Legal Officer Chief Legal Officer | May 05 | Option | 6.89 | 4,132 | 28,469 | 1,332 | 05/09/23 |
Miller Deborah Ann | Chief Legal Officer Chief Legal Officer | Apr 17 | Sell | 29.74 | 2,000 | 59,480 | 04/19/23 | |
Miller Deborah Ann | Chief Legal Officer Chief Legal Officer | Apr 17 | Option | 6.89 | 2,000 | 13,780 | 2,000 | 04/19/23 |
Noci Darlene | Chief Development Of.. Chief Development Officer | Aug 15 | Option | 1.08 | 2,596 | 2,804 | 2,596 | 08/17/22 |
Noci Darlene | Chief Development Of.. Chief Development Officer | Aug 15 | Sell | 17.02 | 2,596 | 44,184 | 08/17/22 | |
Noci Darlene | Chief Development Of.. Chief Development Officer | Jul 15 | Option | 1.08 | 4,200 | 4,536 | 318 | 07/19/22 |
Noci Darlene | Chief Development Of.. Chief Development Officer | Jul 15 | Sell | 17.37 | 4,200 | 72,954 | 07/19/22 | |
Shair Matthew | Director Director | Jul 13 | Sell | 18.27 | 2,100 | 38,367 | 2,162,598 | 07/15/22 |
Noci Darlene | See Remarks See Remarks | Jul 07 | Option | 1.08 | 16,800 | 18,144 | 16,800 | 07/08/22 |
Noci Darlene | See Remarks See Remarks | Jul 07 | Sell | 17.61 | 16,800 | 295,848 | 07/08/22 | |
Noci Darlene | See Remarks See Remarks | Feb 15 | Option | 1.08 | 4,200 | 4,536 | 4,200 | 02/16/22 |
Noci Darlene | See Remarks See Remarks | Feb 15 | Sell | 17.17 | 4,200 | 72,114 | 02/16/22 |